Immunomodulation in multiple sclerosis: From immunosuppression to neuroprotection

Trends in Pharmacological Sciences

Volumn 24, Issue 3, 2003, Pages 131-138

  Neuhaus, Oliver ^a   Archelos, Juan J ^b   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANTIBODY; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CADHERIN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GLATIRAMER; GLUCOCORTICOID; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; INTERFERON BETA SERINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; NEUROTROPHIC FACTOR; PREDNISOLONE; RILUZOLE; SELECTIN; SIMVASTATIN; STAT1 PROTEIN; STAT2 PROTEIN;

APOPTOSIS; CLINICAL TRIAL; DEMYELINATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENOMICS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NEUROPROTECTION; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL;

EID: 0344987883     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00028-2     Document Type: Review

References (79)

1. Noseworthy J.H., et al. Medical progress: multiple sclerosis. New Engl. J. Med. 343:2000;938-952.
2. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain. 120:1997;865-916.
3. O'Connor K.C., et al. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21:2001;81-92.
4. Hemmer B., et al. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3:2002;291-301.
5. Lassmann H., et al. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7:2001;115-121.
6. Hohlfeld R., et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 107:2000;161-166.
7. Schwartz M., et al. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 22:1999;295-299.
8. Paty D.W. Interferon beta-1b. Hawkins C.P., Wolinsky J.S. Principles of Treatments in Multiple Sclerosis. 2000;24-37 Butterworth-Heinemann.
9. Wolinsky J.S. Glatiramer acetate. Hawkins C.P., Wolinsky J.S. Principles of Treatments in Multiple Sclerosis. 2000;71-94 Butterworth-Heinemann.
10. Goodin D.S. Therapeutic developments in multiple sclerosis. Expert Opin. Investig. Drugs. 9:2000;655-670.
11. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
12. Jacobs L.D., et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann. Neurol. 39:1996;285-294.
13. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504.
14. Johnson K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
15. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16:2002;183-200.
16. Cruveilhier J. Anatomie pathologique du corps humain; descriptions avec figures lithographiées et coloriées; des diverses alterations morbides dont le corps humain est susceptible. 1835;J.B. Bailliere.
17. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:2001;762-764.
18. Davidson A., Diamond B. Autoimmune diseases. New Engl. J. Med. 345:2001;340-350.
19. Sawcer S., et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain. 125:2002;1337-1347.
20. Benoist C., Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2:2001;797-801.
21. Lang H.L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3:2002;940-943.
22. + T cells in the cerebrospinal fluid from multiple sclerosis patients. Brain. 125:2002;538-550.
23. Archelos J.J., et al. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47:2000;694-706.
24. Trapp B.D., et al. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12:1999;295-302.
25. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25:2002;532-537.
26. Medana I., et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159:2001;809-815.
27. Bitsch A., et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 123:2000;1174-1183.
28. Bjartmar C., Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14:2001;271-278.
29. Bar-Or A., et al. Molecular pathogenesis of multiple sclerosis. J. Neuroimmunol. 100:1999;252-259.
30. Montalban X. Do steroids have a long-term benefit? Thompson A.J., et al. Multiple Sclerosis - Clinical Challenges and Controversies. 1997;155-167 Martin Dunitz.
31. Barnes P.J. Molecules in focus - nuclear factor-κB. Int. J. Biochem. Cell Biol. 29:1997;867-870.
32. Gold R., et al. Mechanism of action of glucocorticosteroid homones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 117:2001;1-8.
33. Deisenhammer F., et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 52:1999;1239-1243.
34. Buchwalder P.A., et al. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 20:2000;857-866.
35. Durelli L., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 359:2002;1453-1460.
36. Coyle P.K., Hartung H.P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult. Scler. 8:2002;2-9.
37. Panitch H., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The Evidence Trial. Neurology. 59:2002;1496-1506.
38. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology. 59:2002;802-808.
39. Karpusas M., et al. The structure of human interferon-b: implications for activity. Cell. Mol. Life Sci. 54:1998;1203-1216.
40. Hohlfeld R. Therapeutic strategies in multiple sclerosis. I. Immunotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;1697-1710.
41. Liu Z., et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J. Neuroimmunol. 112:2001;153-162.
42. Neuhaus O., et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 56:2001;702-708.
43. Wiles C.M., et al. Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatry. 72:2002;440-448.
44. Stangel M., Hartung H.P. Despair of repair. J. Neurol. Neurosurg. Psychiatry. 72:2002;1-4.
45. Jain K.K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin. Investig. Drugs. 9:2000;1139-1149.
46. Hartung H.P., et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet. 360:2002;2018-2025.
47. Neuhaus O., et al. Multiple sclerosis: immunological effects of mitoxantrone in vitro reveal antigen-presenting cells as major targets. Eur. J. Neurol. 9:(suppl. 2):2002;130.
48. Hong J.C., Kahan B.D. Immunosuppressive agents in organ transplantation: past, present, and future. Semin. Nephrol. 20:2000;108-125.
49. Weiner H.L., Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8:2002;142-154.
50. Archelos J.J., et al. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22:1999;30-38.
51. Hynes R.O. Cell adhesion: old and new questions. Trends Cell Biol. 9:1999;M33-M37.
52. Tubridy N., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 53:1999;466-472.
53. Miller D., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl. J. Med. 348:2003;15-23.
54. Jackson D.Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 8:2002;1229-1253.
55. Kwak B., et al. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402.
56. Neuhaus O., et al. Statins as immunomodulators: comparison with interferon-beta1b in MS. Neurology. 59:2002;990-997.
57. Youssef S., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:2002;78-84.
58. Weitz-Schmidt G., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:2001;687-692.
59. Thoenen H., Sendtnder M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5:2002;1046-1050.
60. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 18:1995;223-253.
61. Villoslada P., et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med. 191:2000;1799-1806.
62. Ransohoff R.M., et al. Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol. 23:2002;512-516.
63. Linker R.A., et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8:2002;620-624.
64. De Keyser J., et al. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 22:1999;535-540.
65. Kappos L. Combination of drugs. Mult. Scler. 1:1996;400-403.
66. Lublin F.D., Reingold S.C. Combination therapy for treatment of multiple sclerosis. Ann. Neurol. 44:1998;7-9.
67. Polman C.H., Uitdehaag B.M.J. Drug treatment of multiple sclerosis. Br. Med. J. 321:2000;490-494.
68. Ziemssen T., et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain. 125:2002;2381-2391.
69. Krance R., Brenner M. BMT beats autoimmune disease. Nat. Med. 4:1998;153-155.
70. Fassas A., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J. Neurol. 249:2002;1088-1097.
71. Hohlfeld R. How promising is hematopoetic stem cell transplantation in multiple sclerosis? J. Neurol. 249:2002;1147-1149.
72. Halfpenny C., et al. Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurol. 1:2002;31-40.
73. Mitome M., et al. Towards the reconstruction of central nervous system white matter using neural precursor cells. Brain. 124:2001;2147-2161.
74. Franklin R.J., et al. What roles do growth factors play in CNS remyelination? Prog. Brain Res. 132:2001;185-193.
75. Barres B.A. A new role for glia: generation of neurons! Cell. 97:1999;667-670.
76. Chang A., et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New Engl. J. Med. 346:2002;165-173.
77. Demerens C., et al. Eliprodil stimulates CNS myelination - new prospects for multiple sclerosis? Neurology. 52:1999;346-350.
78. Pitt D., et al. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:2000;67-70.
79. Martin R., et al. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat. Immunol. 2:2001;785-788.